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Accumulation of toxic metabolites in hereditary tyrosinemia type I (HT1) patients leads to chronic DNA
damage and the highest risk for hepatocellular carcinomas (HCCs) of any human disease. Here we show
that hepatocytes of HT1 mice exhibit a profound cell-cycle arrest that, despite concomitant apoptosis resis-
tance, causes mortality from impaired liver regeneration. However, additional loss of p21 in HT1 mice
restores the proliferative capabilities of hepatocytes and renal proximal tubular cells. This growth response
compensates cell loss due to uninhibited apoptosis and enables animal survival but rapidly leads to HCCs,
renal cysts, and renal carcinomas. Thus, p21’s antiproliferative function is indispensable for the suppression
of carcinogenesis from chronically injured liver and renal epithelial cells and cannot be compensated by
apoptosis.INTRODUCTION
DNA-damaged cells are prone to malignant transformation and
are therefore frequently aborted by apoptosis. Alternatively, if
the damage is limited, cell survival and restoration of genomic
integrity might be favorable. This requires temporary cell-cycle
arrest and protection from apoptosis while DNA repair is occur-
ring. Remarkably, both antiproliferative as well as antiapoptotic
functions are combined in the cell-cycle regulator p21 (Gartel
and Tyner, 2002). Since disabled apoptosis is assumed to be anadjuvant of genetic alterations, especially if the DNA-damaging
stimulus persists, it has been suggested that the antiapoptotic
effect of p21 could provide the grounds for carcinogenesis (Zhi-
votovsky and Kroemer, 2004). Therefore, sensitization toward
apoptosis by inhibition of p21 may be a powerful strategy
for the treatment of cancer (Weiss, 2003). However, p21 was
originally identified as the effector of p53’s cell-cycle inhibitory
capacity, and, since unrestricted proliferation is another pro-
moter of cancer (Zhivotovsky and Kroemer, 2004), the interplay
of apoptosis and proliferation in p21-deficient cancer cellsSIGNIFICANCE
p53 prevents carcinogenesis by inducing cell-cycle arrest or apoptosis. The antiproliferative effect of p53 is mediated by
p21, which also has antiapoptotic function to enable restoration of genomic integrity. Apoptosis resistance has been rec-
ognized as a major carcinogenic factor, and attenuation of p21 may enhance the effectiveness of chemotherapy. Contro-
versy exists as to whether the cancer-suppressing effect of p53 is mainly attributable to its cell-cycle inhibitory or apopto-
sis-inducing capacity. Here we show that the antiproliferative function of p21 is indispensable in cancer-prone epithelial
tissues such as liver and kidney. Apoptosis alone fails to prevent carcinogenesis from chronically injured p21-deficient cells.
Our results highlight the essential role of cell-cycle control in intrinsic suppression and targeted therapy of cancer.Cancer Cell 14, 59–67, July 2008 ª2008 Elsevier Inc. 59
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p21 Prevents Cancer in Liver and Kidneyremains to be elucidated before such therapeutic strategies
can be pursued. In particular, regenerative capabilities such
as those inherent to the liver must be rigorously controlled. In
chronic liver diseases, accumulation of DNA damage results
in dysplastic hepatocytes that eventually escape cancer control
mechanisms and progress to hepatocellular carcinomas
(HCCs) (Bruix et al., 2004). For example, the chronic liver injury
inflicted by hereditary tyrosinemia type I (HT1) is associated
with the highest risk for HCCs of any human disease (Russo
and O’Regan, 1990). HT1 is due to mutations in the gene en-
coding fumarylacetoacetate hydrolase (Fah), the enzyme that
completes tyrosine degradation, leading to accumulation of
metabolites such as fumarylacetoacetate (FAA), which is a po-
tent mutagenic agent (Jorquera and Tanguay, 1997). Accumu-
lation of FAA can be prevented by blocking proximal tyrosine
degradation with the drug 2-(2-nitro-4-trifluoromethylbenzoyl)-
1,3-cyclohexanedione (NTBC) (Holme and Lindstedt, 2000).
Unfortunately, NTBC therapy does not appear to be completely
effective since both Fah-deficient mice and humans have been
shown to develop hepatocyte dysplasias that potentially give
rise to HCCs (Al-Dhalimy et al., 2002; Grompe et al., 1995;
van Spronsen et al., 2005). Apart from the liver, Fah is specifi-
cally expressed in kidney proximal tubular cells, which have re-
generative capabilities similar to hepatocytes. Modeling the
chronic cell injury inherent to most human disease states, we
identify p21’s antiproliferative activity as essential for cell-cycle
Figure 1. Fah Deficiency Causes Cell-Cycle Arrest
Associated with DNA Damage and Induction of p21
(A) In contrast to wild-type cells (upper panel), Fah-deficient
hepatocytes (lower panel) refrain from entry into S phase in re-
sponse to 2/3 partial hepatectomy (PH), as evident from lack
of BrdU labeling (brown, arrowhead in lower panel). Scale
bars = 100 mm.
(B) p21 but not p27 protein is induced in Fah/ mice after 2
weeks of NTBC withdrawal. p21 levels due to Fah deficiency
markedly exceed those associated with the physiological
halt of liver regeneration 72 hr after PH (H) in Fah/ mice on
NTBC. p21 protein levels are maximally induced in Fah/
mice off NTBC for 2 weeks since they fail to increase after
further stimulation by PH.
(C) Comet assay shows that NTBC withdrawal (gray columns)
causes DNA damage (tail moment) in Fah/ and Fah/,
p21/ livers. Fah/,p21/ mice exhibit increased levels of
DNA damage both on (white columns) and off NTBC. Error
bars represent mean ± SD.
(D) DNA damage in Fah/ and even more so in Fah/,p21/
hepatocytes is reflected by induction of p53.
(E and F) p21 protein induced by Fah deficiency is distributed
between cytoplasm and nucleus as evident from western
blot comparison to c-Jun, which is strictly limited to the nucleus
(E), and p21 immunocytochemistry (brown, left panel in [F]) on
plated hepatocytes costained for DNA with SYBR green I
(green, right panel in [F]). Inset in left panel of (F) shows absence
of p21 in a Fah/,p21/ hepatocyte. Scale bars = 25 mm.
arrest and prevention of carcinogenesis in hepato-
cytes and renal proximal tubular cells. While
apoptosis resistance maintained by p21 might
contribute to dysplastic transformation of DNA-
damaged liver and kidney epithelial cells, induced
apoptosis following loss of p21 clearly fails to sufficiently elim-
inate cancer-initiating cells.
RESULTS
Failed Regeneration of Fah-Deficient Hepatocytes
Is Associated with DNA Damage and Induction of p21
Fah-deficient mice taken off the drug NTBC mimic both the liver
failure and kidney pathology of the human disease (Grompe
et al., 1993) and have been shown to provide a strong selective en-
vironment for Fah-expressing cells (Overturf et al., 1996). We hy-
pothesized that repopulation of the mutant host liver with wild-
type donor cells requires either substantial cell death (Mallet
et al., 2002) or an impaired proliferative response (Guo et al.,
2002) in Fah-deficient hepatocytes. We previously showed that
Fah-deficient hepatocytes (Vogel et al., 2004) as well as renal prox-
imal tubular cells (Luijerink et al., 2004) are not susceptible to
cell death but rather display a profound apoptosis-resistance
phenotype. Therefore, to test whether positive selection of
Fah-expressing cells is facilitated by inhibited proliferation of
Fah-deficient hepatocytes, we performed labeling studies with 5-
bromo-2-deoxyuridine (BrdU) after 2/3 partial hepatectomy (PH)
(Greene and Puder, 2003) in Fah/ mice that had been off NTBC
for 2 weeks. Surprisingly, no BrdU-labeled hepatocytes could be
detected at 40 hr, the time point with the largest number of hepato-
cytes in S phase after PH in mice (Mitchell et al., 2005) (Figure 1A).60 Cancer Cell 14, 59–67, July 2008 ª2008 Elsevier Inc.
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p21 Prevents Cancer in Liver and KidneyHepatocyte proliferation was not only delayed but blocked in
these animals, as they showed no signs of liver regeneration
and invariably died from liver failure within 4 days after PH (data
not shown).
To identify genes instrumental in the cell-cycle arrest of Fah-
deficient hepatocytes, we performed microarray analyses on
liver samples from wild-type and Fah/ mice on or off NTBC
for 2 weeks (Table 1; see also Figure S1A available online). As
reported previously (Luijerink et al., 2003), Fah deficiency af-
fected the expression of a large number of genes including pro-
liferation-associated genes such as Ki67, c-jun, and c-myc.
However, within the cluster of genes that regulate cell-cycle
progression, p21 mRNA (Table 1) as well as protein
(Figure 1B) levels were most significantly induced after NTBC
withdrawal.
Wild-type mouse liver has undetectable levels of p21 mRNA
and protein (Albrecht et al., 1998), but high quantities are com-
mon in liver diseases caused by toxic agents (Bartosiewicz
et al., 2001) or viral infections (Wagayama et al., 2001). This
induction of p21 is most likely due to DNA damage, and FAA,
the accumulating substrate for Fah, is known to be a
potent oxidizing agent that leads to genomic instability in vitro
(Jorquera and Tanguay, 1997, 2001). To assess the DNA-dam-
aging effect of FAA in vivo, we performed comet assay (Singh
et al., 1988) on liver samples from Fah/ mice after 2 weeks
of NTBC withdrawal. The tail moment in these analyses indica-
ted that Fah deficiency was associated with profound DNA
damage (Figure 1C). Interestingly, and in accordance with the
increased late-onset cancer incidence of p21/ mice (Martin-
Caballero et al., 2001), animals deficient in both Fah and p21
(Fah/,p21/) showed increased levels of DNA damage not
only off but also on NTBC. Elevated levels of p53 mRNA and pro-
tein were also present in Fah/ livers, and therefore, in analogy
to findings in human HCCs (Shi et al., 2000), the activation of p21
was most likely mediated by this classical pathway (Table 1;
Figure 1D).
Previously, the antiapoptotic and antiproliferative activities of
p21 have been correlated with its localization in the cytoplasm
or the nucleus, respectively (Zhou et al., 2001). In Fah deficiency,
p21 was abundant in both cellular compartments (Figures 1E
and 1F). Thus, we wished to determine whether the cell-cycle
arrest and apoptosis-resistance phenotype (Vogel et al., 2004)
of Fah-deficient hepatocytes are dependent on p21.
Cell-Cycle Arrest of Fah-Deficient Hepatocytes
Is Caused by Induced p21
Microarray analyses and cell-cycle distribution of Fah/ hepa-
tocytes after NTBC withdrawal were suggestive of cell-cycle
inhibition by p21 (Table 1; Figure S1B). To test this, livers of
Fah/ and Fah/,p21/ mice that were off NTBC for 2 weeks
and had received oral BrdU throughout the second week were
compared. Fah/,p21/ livers showed marked proliferation
of hepatocytes, whereas Fah/ or wild-type livers contained
very few BrdU-labeled cells (Figure 2A). Similar results were
obtained with Ki67 (a general proliferation marker) (Figure 2B;
Figure S2) and phosphorylated histone H3 (a mitosis-specific
antigen) (Figure 2C) staining. Hence, p21 is needed to block
hepatocyte proliferation after DNA damage inflicted by Fah
deficiency.Fah/ mice invariably die from liver failure due to extensive
hepatocellular necrosis accompanied by progressive weight
loss within 8 weeks after NTBC withdrawal (Grompe et al., 1995).
When NTBC was discontinued in Fah/,p21/ mice, their
weight loss at first paralleled that of their Fah/ littermates but
then reached a plateau between 5 and 6 weeks (data not shown).
Surprisingly, after 6 weeks of NTBC withdrawal, Fah/,p21/
animals began to regain their weight and, most importantly, sur-
vived more than 16 weeks of NTBC withdrawal (Figure 2D). This
recovery was not reflected by normalization of serum liver func-
tion tests (data not shown), and we believe that the recovery of
Fah/,p21/ mice is due to continuous liver regeneration,
which maintains a critical level of liver function and allows subse-
quent metabolic adaptation. Some of the weight gain, however,
was due to an increasing liver tumor burden (see below), and the
animals eventually had to be euthanized. These results show that
p21 is the key protein establishing and maintaining cell-cycle
arrest in Fah deficiency and that blocked hepatocyte prolifera-
tion resulting in insufficient hepatocellular mass contributes to
lethality in this disease. Interestingly, by performing PH in
Fah/ mice at various time points after NTBC withdrawal, we
found that p21 must be maximally induced in order to counteract
the strong regenerative stimuli elicited by PH (Michalopoulos
Table 1. Hepatic Gene Expression Analysis of Wild-Type
Compared to Fah/ or Fah/,p21/ Mice after Two Weeks of
NTBC Withdrawal
Wild-Type Fah/ off NTBC
Fah/,p21/
off NTBC
p21 n/a
p53
p15
p16
p19a
p27
Ki67a
c-jun
c-myc
Cyclin A2a
Cyclin B1a
Gadd45a
Mdm2
Apaf-1
Bax
Rtp801
Puma
Noxaa
Afp
Albumin
Gene expression levels are shown on a logarithmic scale: 10E(number of
, with = 0.5). The effect of NTBC on hepatic gene expression is re-
stricted to Fah deficiency (data not shown). Hence, gene expression
levels in wild-type mice on water represent findings in wild-type, Fah/,
and Fah/,p21/ mice on NTBC. Raw microarray data are provided in
Figure S1A.
a Gene differentially expressed between Fah/ and Fah/,p21/ mice.Cancer Cell 14, 59–67, July 2008 ª2008 Elsevier Inc. 61
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p21 Prevents Cancer in Liver and Kidneyand DeFrances, 1997) (Figure 2E). Similarly, threshold p21 levels
might be needed to antagonize the oncogenic gene expression
in hepatocytes injured by Fah deficiency (Table 1).
Apoptosis Resistance of Fah-Deficient Hepatocytes
Is p21 Dependent
Upon NTBC withdrawal, Fah/ hepatocytes acquire profound
resistance to multiple death triggers (Vogel et al., 2004). In
contrast to this finding, TdT-mediated dUTP nick-end labeling
(TUNEL) revealed many apoptotic hepatocytes in liver sections
from Fah/,p21/ mice 2 weeks after NTBC discontinuation
(Figure 3A). Apoptosis promoters known to be transcriptionally
regulated by p53 such as Apaf-1, Bax, and Puma were moder-
ately induced by Fah deficiency regardless of p21 status,
with the exception of Noxa, which appeared to be repressed in
Fah/ hepatocytes and was highly expressed in Fah/,p21/
cells (Table 1). These results suggest that transcriptional
repression of Noxa may be a key factor in apoptosis resistance
caused by p21 induction. Accordingly, Fah/,p21/ but not
Fah/mice showed massive apoptotic hepatocyte death follow-
ing intraperitoneal injection of a monoclonal antibody that binds
and activates Fas antigen (Jo2) (Figure 3B), which was accompa-
nied by activation of caspase-3 (Figure 3C). These findings show
that p21 causes the hepatocyte apoptosis resistance observed
in Fah deficiency (Figure 3D). Remarkably, Fah/,p21/ mice
survived by compensating hepatocyte loss due to Fas-mediated
apoptosis with increased mitotic divisions (Figure 3E).
p21 Is Needed to Prevent Formation of Liver Cancer
from Chronically Injured Hepatocytes
Apoptosis resistance and persistent proliferation of hepatocytes
with damaged DNA have both been recognized as key factors in
formation of HCCs (Montalto et al., 2002). Since p21 is capable
of counteracting both cell death and cell division, its loss could
result in either increased or decreased tumor formation, depend-
ing on which function is dominant. To first determine p21’s
impact on early cancer-initiating events, we examined livers of
Fah/ and Fah/,p21/ mice that had been off NTBC for 2
weeks for the expression of a-fetoprotein (AFP) (Table 1; Figures
4A–4C). AFP is expressed during liver development but is
repressed in adult liver (Figure 4A). AFP is upregulated in 80%
of human HCCs, but its expression is initiated in dysplastic
hepatocytes that are precancerous (Montalto et al., 2002). Histo-
logical evaluation showed a similar frequency of AFP-positive
Figure 2. p21 Represses the Regenerative
Response of Hepatocytes to Cell Damage
Inflicted by Fah Deficiency
(A) Wild-type liver (left panel) contains very few
proliferating (brown, BrdU labeling) hepatocytes
(arrowhead). Upon NTBC withdrawal, Fah/ he-
patocytes (middle panel) fail to enter the S phase
of the cell cycle, whereas Fah/,p21/ hepato-
cytes (right panel) show massive proliferation.
Note dysplasia of Fah/ and Fah/,p21/
hepatocytes off NTBC compared to wild-type
cells. Scale bars = 100 mm.
(B and C) Immunohistochemistry (brown staining)
for Ki67 (B) and phosphorylated histone H3 (C)
show that despite liver injury induced by NTBC
withdrawal, Fah/ hepatocytes (middle panels)
exhibit a proliferation arrest similar to wild-type
cells (arrowheads, left panels) that is lifted in livers
deficient in both Fah and p21 (right panels). Pro-
gression of Fah/,p21/ hepatocytes into the
G2 and M phases of the cell cycle is apparent
from both Ki67 (right panel in [B]) and phosphory-
lated histone H3 (right panel in [C]) staining. Quan-
tification of Ki67-labeled hepatocytes is provided
in Figure S2. Scale bars = 100 mm.
(D) Kaplan-Meier plot shows that Fah/,p21/
mice (blue line), but not their Fah/ littermates
(red line), survive beyond the critical phase of
NTBC withdrawal. Ten mice were analyzed for
each genotype.
(E) The cell-cycle inhibitory function of p21 in he-
patocytes is dose dependent. Fourteen days after
NTBC withdrawal, p21 protein levels are maxi-
mally induced. These p21 protein levels are
needed for suppression of hepatocyte prolifera-
tion in Fah/ mice after PH, as levels of p21 pro-
tein found after 4 or 8 days off NTBC fail to prevent
liver regeneration (data not shown). Three mice
were analyzed for each time point, and a represen-
tative western blot is shown. a-actin serves as
loading control.62 Cancer Cell 14, 59–67, July 2008 ª2008 Elsevier Inc.
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p21 Prevents Cancer in Liver and Kidneyhepatocytes in Fah/ and Fah/,p21/ mice (Figures 4B and
4C). AFP expression is tightly correlated with genomic instability
in dysplastic hepatocytes and HCCs in mice (Calvisi et al., 2004).
Therefore, p21’s impact on genomic stability (Figure 1C) did not
suffice to prevent dysplastic changes. However, while only dys-
plastic hepatocytes but no tumors were found in Fah/ controls,
all Fah/,p21/ mice developed multiple HCCs by 7–8 weeks
after NTBC withdrawal (Figures 4D–4F). Histologically, these
HCCs were equivalent to human HCCs of WHO grade
2–3 (Hirohashi et al., 2000). Molecular analyses revealed that
these HCCs retained p53 function and induced expression of
other cell-cycle regulators including p15, p16, and p19, which
suggests a predominant role of p21’s cell-cycle inhibitory func-
tion in liver cancer prevention (Figures S4A and S4B).
Fah/ mice die of liver failure at around 8 weeks after NTBC
withdrawal (Figure 2D). To compare tumor onset in Fah/ and
Fah/,p21/ mice under less acute conditions, we treated
cohorts of mice with 5% of the normal NTBC dose. This leads
to HCCs in Fah/ mice within 1 year (Al-Dhalimy et al., 2002;
Grompe et al., 1995). In contrast, Fah/,p21/ mice developed
HCCs after only 8 weeks on low-dose NTBC. Although these
tumors were smaller and fewer than in Fah/,p21/ mice com-
pletely off NTBC, they exhibited the same malignant phenotype
(Figure S4C). Taken together, under conditions mimicking
chronic human liver disease, the antiproliferative effect of p21
appears to be more important for prevention of HCCs than its
antiapoptotic function.
Chronically Injured Renal Proximal Tubular Cells
Give Rise to Cysts and Cancer in the Absence of p21
In addition to hepatocytes, the complete tyrosine degradation
pathway including Fah is also expressed in proximal tubular
epithelial cells in the kidney (Grompe et al., 1993). In the embry-
onic kidney, the growth-inhibitory effect of polycystin-1, the
gene product of Pkd1, has been suggested to be mediated by
transcriptional activation of p21 (Bhunia et al., 2002). Loss of pol-
ycystin-1 results in renal cyst formation that begins at embryonic
day 15 in proximal tubular cells and progresses to replace the
entire renal parenchyma by day 8 postpartum (Lu et al., 1997).
Therefore, the renal phenotypes of Fah/,p21/ and Fah/
mice were compared. In mice lacking only Fah, NTBC withdrawal
resulted in renal tubular injury with aminoaciduria and mild kidney
enlargement (data not shown) (Grompe et al., 1993). In contrast,
Fah/,p21/ mice developed macroscopically detectable
Figure 3. Apoptosis Resistance Inherent to
Fah Deficiency Depends on p21
(A and B) In contrast to wild-type (left panels) or
Fah/ (middle panels) mice, Fah/,p21/ (right
panels) animals exhibit increased numbers of
TUNEL-positive hepatocytes (brown, arrowheads)
after 2 weeks off NTBC (A), which can be further
increased by application of a monoclonal antibody
(Jo2) recognizing Fas (B).
(C) Hepatic apoptosis response in Fah-deficient
mice depends on p21 and NTBC status. Sponta-
neous caspase-3 activation is detectable in liver
lysates from Fah/,p21/ mice off NTBC for 4
weeks (column 5) but not 2 weeks (column 4). In
contrast, caspase-3 activation is undetectable in
liver lysates from Fah/,p21/ and Fah/ mice
on NTBC (columns 3 and 1) or Fah/ mice after
2 or 4 weeks of NTBC withdrawal (column 2).
Jo2 injection induces massive caspase-3 activa-
tion in both Fah/ and Fah/,p21/ mice on
NTBC (columns 6 and 8). Fah/ mice off NTBC
show resistance to Jo2-induced apoptosis
(column 7) that is abrogated in Fah/,p21/
mice off NTBC (column 9). Error bars represent
mean ± SD.
(D) Quantification of the percentage of TUNEL-
positive hepatocytes in untreated (dark gray
columns) and Jo2-injected (light gray columns)
mice.
(E) Injection of Jo2 is followed by BrdU labeling
(brown staining) of many Fah/,p21/ hepato-
cytes (right panel), while very few Fah/ hepato-
cytes (left panel, arrowhead) exhibit compensa-
tory proliferation.
Three mice were analyzed for each genotype and
treatment regimen. Representative stainings are
shown, and corresponding H&E stainings are
provided in Figure S3. Scale bars = 100 mm.Cancer Cell 14, 59–67, July 2008 ª2008 Elsevier Inc. 63
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p21 Prevents Cancer in Liver and KidneyFigure 4. DNA-Damaged Hepatocytes Give
Rise to Liver Cancer in the Absence of p21
(A–C) a-fetoprotein (AFP) immunohistochemistry
(brown staining) indicates that wild-type livers (A)
lack dysplastic hepatocytes while similar numbers
of these cells are present in Fah/ (B) and Fah/,
p21/ (C) mice off NTBC. Scale bars = 100 mm.
(D) Ki67 immunohistochemistry (brown staining)
marking proliferation of dysplastic hepatocytes
in a Fah/,p21/ mouse off NTBC. Scale bar =
50 mm.
(E) Representative H&E staining of WHO grade 3
hepatocellular carcinoma (HCC) in a Fah/,
p21/ mouse off NTBC. Scale bar = 50 mm.
(F) Median lobe of a Fah/,p21/ mouse off
NTBC after clonal progression of dysplastic hepa-
tocytes to cancer nodules.cysts (Figure 5A) comprising large areas of the renal parenchyma
(Figures 5B) within 10 weeks after NTBC withdrawal. In addition
to cyst formation, renal carcinomas were present in 80% (8 of
10) of these mice after only 12 weeks of NTBC withdrawal (Fig-
ures 5C–5F). Histologically, these carcinomas corresponded to
grade 2–3 of the Fuhrman classification for human renal cell
carcinoma (Fuhrman et al., 1982). Clones of dysplastic renal
proximal tubular cells (Figure 5C) exhibiting high proliferative
activity (Figure 5D) gave rise to the renal cell carcinomas (Figures
5E and 5F). Dysplastic proliferating renal proximal tubular cells
were not detected in the p21-expressing Fah/ controls (data
not shown). Moreover, renal carcinomas do not occur in Fah/
mice, even after 1 year of low-dose NTBC treatment, which
invariably causes HCCs (Figure S4C) (Al-Dhalimy et al., 2002;
Grompe et al., 1995).
DISCUSSION
Our results show that p21 alone is sufficient to suppress the
extraordinary regenerative capacity of hepatocytes and kidney64 Cancer Cell 14, 59–67, July 2008 ª2008 Elsevier Inc.proximal tubular cells. In the subacute or chronic injury state
as modeled here, loss of p21 was not compensated by other
cell-cycle inhibitors. In the absence of p21, proliferation of cells
with DNA damage resulted in rapid cancer formation. The rapid
development of renal and hepatic carcinomas seen here is not
found in any other experimental system and suggests that p21
may be an important target for silencing in tumors derived from
these tissues. In support of this hypothesis, recent clinical obser-
vations suggest that loss of p21 expression marks the transition
from hepatocyte dysplasia to HCC (Plentz et al., 2007). Our
finding that the antiproliferative effect of p21 is dose dependent
indicates that complete abolishment of p21 by genetic mutation
is not needed to unlock proliferation. Lowering the levels of p21
protein suffices, and epigenetic changes such as promoter
methylation, microRNA-mediated silencing, and mechanisms
regulating protein distribution and degradation may therefore
cause HCCs by weakening p21-dependent cell-cycle arrest in
cells with DNA damage. Such a threshold would explain findings
that higher levels of p21 are associated with better prognosis in
human HCCs (Kao et al., 2007).Figure 5. Unrestricted Proliferation of DNA-
Damaged Renal Proximal Tubular Cells Re-
sults in Formation of Cysts and Carcinomas
(A and B) Fah/,p21/ mice develop renal cysts
after NTBC withdrawal.
(A) Large cysts extend to the surface of the kidney
(scale in inches).
(B) Cystically dilated proximal convoluted tubules
and cysts. Scale bar = 200 mm.
(C–F) Progression of renal tubular dysplasia to
renal carcinomas in Fah/,p21/mice off NTBC.
(C) Dysplastic renal proximal tubular cells with large
and hyperchromatic nuclei. Scale bar = 50 mm.
(D) Immunohistochemistry for Ki67 (brown staining)
shows cluster of proliferating dysplastic renal epi-
thelial cells. Scale bar = 50 mm.
(E) Kidney cancer nodule compressing the sur-
rounding parenchyma. Scale bar = 100 mm.
(F) Representative H&E staining of grade 2–3
(Fuhrman classification) renal cell carcinoma.
Scale bar = 50 mm.
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p21 Prevents Cancer in Liver and KidneyOn the other hand, we find that accumulation of p21 prevents
hepatocyte regeneration and leads to liver failure and death in
Fah-deficient mice. Analogously, transgenic overexpression of
p21 impairs hepatocyte proliferation in liver development and
after partial hepatectomy (Wu et al., 1996). Moreover, p21 has
been suggested to inhibit hepatocyte regeneration in chronic
human liver diseases leading to cirrhosis such as autoimmune
and viral hepatitis (Lunz et al., 2005) and nonalcoholic steatohe-
patitis (Richardson et al., 2007). Therefore, inappropriately high
levels of p21, while protective against cancer, may have adverse
consequences for liver homeostasis or regeneration. Together,
these findings indicate that levels of p21 protein must be tightly
regulated in the liver in order to balance regenerative fitness with
cancer risk.
Resistance to apoptosis has recently emerged as a factor
contributing to cancer initiation and progression. Because p21
can suppress apoptosis, therapeutic strategies aimed at attenu-
ation of p21 in malignant cells have been proposed (Weiss, 2003).
Indeed, our results confirm that lack of p21 renders Fah-deficient
cells susceptible to cell death. However, apoptosis failed to
dispose of enough cancer-initiating cells, and the net result of
p21 deficiency was increased, not decreased, carcinogenesis.
Therefore, overcoming apoptosis resistance by suppression of
p21 would require additional antiproliferative means. Alterna-
tively, specific targeting of the antiapoptotic function of p21 while
maintaining or enhancing its cell-cycle inhibitory capacity might
be a safer and more effective anticarcinogenic strategy.
EXPERIMENTAL PROCEDURES
Mice
FahDexon5 (129S4) (Grompe et al., 1993) and B6;129S2-Cdkn1atm1Tyj/J (Brugar-
olas et al., 1995) (The Jackson Laboratory) mice were crossed to generate
Fah/,p21+/ breeders from which all Fah/ and Fah/,p21/ animals
used in these studies were derived. Drinking water was supplemented with
NTBC (gift from S. Lindstedt) at a concentration of 7.5 mg/ml (Grompe et al.,
1995). Five percent of this normal dose was used for low-dose NTBC treat-
ment. BrdU (Sigma) was either added to the drinking water at a concentration
of 0.8 mg/ml or injected intraperitoneally at 100 mg/g. For apoptosis induction,
animals were injected intraperitoneally with 0.3 mg/g of the monoclonal Fas an-
tibody Jo2 (PharMingen). 2/3 partial hepatectomy was performed by resection
of the left lateral and median liver lobe, residing below and to the left and right
of the gall bladder, respectively. All animal experiments were approved by the
Institutional Animal Care and Use Committee of the Oregon Health & Science
University.
Microarray
Total RNA was isolated from freshly harvested liver samples using the RNeasy
Protect Mini Kit (QIAGEN), and 10 mg was used for production of biotinylated
antisense RNA as described previously (Golub et al., 1999). Labeled RNA
was hybridized to Affymetrix 430A 2.0 or 430 2.0 oligonucleotide arrays
in the Affymetrix Microarray Core of the Oregon Health & Science University
(http://www.ohsu.edu/gmsr/amc/). Data analyses were performed using
Affymetrix Expression Analysis software.
Histology, Immunostaining, and TUNEL Assay
Liver samples were fixed in 10% phosphate-buffered formalin (pH 7.4), dehy-
drated in 100% ethanol, and embedded in paraffin wax at 58C. Sections
(5 mm) were rehydrated and stained with hematoxylin and eosin (H&E). Immu-
nohistochemistry with antibodies for BrdU (DakoCytomation), Ki67 (Novocas-
tra), histone H3 (Ser10) (Upstate), AFP (ICN), and TUNEL assays (ApopTag,
Serological Corporation) were performed as described previously (Vogel
et al., 2004). For immunocytochemistry, single-cell hepatocyte suspensionswere generated by liver collagenase perfusion as reported previously (Overturf
et al., 1996). Hepatocytes were plated in six-well Primaria dishes (Falcon/Bec-
ton Dickinson Labware) at a density of 13 104 cells/cm2. Four hours after plat-
ing, cells were fixed in 4% paraformaldehyde (Sigma) and permeabilized with
0.25% Triton X-100 (Sigma). Blocking was carried out in 10% FCS (Hyclone).
For antigen detection, a goat p21 antibody (Santa Cruz Biotechnology) and an
HRP-conjugated donkey anti-goat antibody (Jackson ImmunoResearch) were
used. Visualization of immunocomplexes was performed with a DAB peroxi-
dase substrate kit (Vector Laboratories), and SYBR green I (Molecular Probes)
was used to dye DNA.
Caspase Activity Assay
Liver lysates were prepared by homogenization in hypotonic buffer (25 mM
HEPES [pH 7.5], 5 mM MgCl2, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluo-
ride). Homogenates were centrifuged at 15,000 rpm for 15 min, and 50 mg al-
iquots of the extracted proteins were tested in triplicate assays by measuring
the proteolytic cleavage of a specific fluorogenic substrate for caspase-3
(CaspACE Assay System, Promega).
Comet Assay
Single-cell gel electrophoresis for the detection of DNA damage in mouse
hepatocytes was performed according to standard procedures (Singh et al.,
1988). Briefly, 10 mg of liver tissue was minced and then homogenized in buffer
(75 mM NaCl, 24 mM EDTA [pH 7.5]) using a loosely fitting Potter-Elvehjem
homogenizer (Bellco Glass). After sedimentation, single cells remaining in
the supernatant were pelleted at 7003 g for 4 min and resuspended in buffer.
Ten microliters of cellular suspension (>13 104 cells) was mixed with 120 ml of
low-melting-point agarose at 37C and then added to normal-melting-point
agarose-coated microscope slides. The slides were immersed in cold lysing
solution overnight and then placed in an electrophoresis tray with an alkaline
solution (300 mM NaOH, 1 mM Na2EDTA [pH 13]) for 10 min to allow DNA to
unwind. Electrophoresis was conducted at room temperature for 15 min at
25V and 300 mA. The slides were washed, stained with ethidium bromide,
and examined at 4003 magnification using a fluorescence microscope. Per
animal, 100 individual cells on two replicate slides were evaluated using Scion
Image software (Scion) combined with an additional comet macro (gift from A.
Rapp). The mean of the tail moment (DNA migration3 tail intensity) was calcu-
lated as a measure of DNA damage (Hartmann et al., 2003). Differences
between mean values were tested for statistical significance (p < 0.05) using
Student’s t test and one-way analysis of variance.
Western Blot
Protein extracts were resolved by SDS-PAGE and transferred onto polyvinyli-
dene difluoride membranes (Millipore). Coomassie staining was used to dem-
onstrate equal protein loading. Western blotting was performed as described
previously (Vogel et al., 2004). Antibodies for p21, p53, c-Jun, and Mdm2 were
purchased from Santa Cruz. Immunolabeled proteins were detected with
a chemiluminescence kit (Bio-Rad) and Hyperfilm enhanced chemilumines-
cence film (Amersham Biosciences).
ACCESSION NUMBERS
Complete microarray results are available at the NCBI Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the accession number
GSE11098.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, one
table, and four figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/14/1/59/DC1/.
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